Pharmacokinetics of clarithromycin after single intravenous and intracrop bolus administrations to broiler chickens

Authors

  • Hanady AwadAllah University of Tripoli
  • Shaban Awidat University of Tripoli
  • Abubakr El-Mahmoudy Benha University

DOI:

https://doi.org/10.14419/ijpt.v4i1.5846

Keywords:

Broiler, Chicken, Clarithromycin, Intracrop, Intravenous, Pharmacokinetics.

Abstract

The pharmacokinetics of clarithromycin at a dose of 7.5 mg/kg body weight was evaluated after single intravenous (i.v.) and intracrop (i.c.) bolus administrations in broilers. An HPLC assay using pure clarithromycin base as a standard was used to measure its concentrations in plasma. Following an i.v. bolus injection, the plasma concentration-time curves of clarithromycin were best represented by two-compartment open models. The drug was rapidly distributed and moderately eliminated with half-lives of distribution (t1/2α) and elimination (t1/2β) of 0.38 and 4.58 h, respectively. The volume of distribution was large with (Vdss) value of 6.89 L. The total body clearance (ClB) was 1.2 L/h. After i.c. bolus administration of the same dose, clarithromycin was moderately absorbed in broilers with an intermediate absorption half-life (T½ab) of 0.72 h with peak plasma concentration (Cmax) of 1.69 μg/ml attained at 1.7 h (Tmax) and systemic bioavailability of 66.54%. The elimination half-life following i.c. administration was 2.11 h. The extent of plasma protein binding percent was 52%. The study recommends the use of clarithromycin in broilers because of its good pharmacokinetic profile indicated by good absorption, bioavailability and plasma concentrations ≥ MICs of many sensitive microorganisms.

References

[1] Abo-El-Sooud K, Fahmy E, Afifi N & El-Aty AA 2012, Pharmacokinetics and bioavailability of azithromycin following intramuscular and oral administrations in broiler chickens. Research Reviews in Biosciences 6, 264-270.

[2] Alvarez-Elcoro S & Enzler MJ 1999, the macrolides: erythromycin, clarithromycin, and azithromycin. In: Mayo Clinic Proceedings: Elsevier. P 613-634.

[3] Amini H & Ahmadiani A 2005, Sensitive determination of clarithromycin in human plasma by high-performance liquid chromatography with spectrophotometric detection. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences 817, 193-197. http://dx.doi.org/10.1016/j.jchromb.2004.12.003.

[4] Baggot J 1995, Pharmacokinetics: disposition and fate of drugs in the body. Veterinary pharmacology and therapeutics 18-52.

[5] Baggot JD 1977, Principles of drug disposition in domestic animals: the basis of veterinary clinical pharmacology: WB Saunders.

[6] Baggot JD 1978a, some aspects of clinical pharmacokinetics in veterinary medicine II. Journal of Veterinary Pharmacology and Therapeutics 1, 111-118. http://dx.doi.org/10.1111/j.1365-2885.1978.tb00314.x.

[7] Baggot JD 1978b, some aspects of clinical pharmacokinetics in veterinary medicine. I. Journal of Veterinary Pharmacology and Therapeutics 1, 5-18. http://dx.doi.org/10.1111/j.1365-2885.1978.tb00300.x.

[8] Bahal N & Nahata MC 1992, the new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Annals of Pharmacotherapy 26, 46-55.

[9] Chu S, Sennello L, Bunnell S, Varga L, Wilson D & Sonders R 1992a, Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrobial Agents and Chemotherapy 36, 2447-2453. http://dx.doi.org/10.1128/AAC.36.11.2447.

[10] Chu SY, Deaton R & Cavanaugh J 1992b, Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrobial Agents and Chemotherapy 36, 1147-1150. http://dx.doi.org/10.1128/AAC.36.5.1147.

[11] Craig W & Suh B 1991, Protein binding and the antimicrobial effects: methods for the determination of protein binding. Antibiotics in laboratory medicine Williams & Wilkins, Baltimore, Md 367-402.

[12] Dorrestein GM 1991, the pharmacokinetics of avian therapeutics. Veterinary Clinics of North America: Small Animal Practice 21, 1241-1264. http://dx.doi.org/10.1016/S0195-5616(91)50135-2.

[13] Ferrero J, Bopp B, Marsh K, Quigley S, Johnson M, Anderson D, Lamm J, Tolman K, Sanders S & Cavanaugh J 1990, Metabolism and disposition of clarithromycin in man. Drug Metabolism and Disposition 18, 441-446.

[14] Grizzle JE 1965, the two-period change-over design and its use in clinical trials. Biometrics 467-480. http://dx.doi.org/10.2307/2528104.

[15] Jacks S, Giguere S, Gronwall R, Brown M & Merritt K 2002, Disposition of oral clarithromycin in foals. Journal of Veterinary Pharmacology and Therapeutics 25, 359-362. http://dx.doi.org/10.1046/j.1365-2885.2002.00420.x.

[16] Katayama M, Nishijima N, Okamura Y, Katayama R, Yamashita T, Kamishina H & Uzuka Y 2012, Interaction of clarithromycin with cyclosporine in cats: pharmacokinetic study and case report. Journal of feline medicine and surgery 14, 257-261. http://dx.doi.org/10.1177/1098612X11435612.

[17] Kohno Y, Yoshida H, Suwa T & Suga T 1989, Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrobial Agents and Chemotherapy 33, 751-756. http://dx.doi.org/10.1128/AAC.33.5.751.

[18] LeBel M 1993, Pharmacokinetic properties of clarithromycin: a comparison with erythromycin and azithromycin. The Canadian Journal of Infectious Diseases 4, 148.

[19] Peters DH, Friedel HA & McTavish D 1992, Azithromycin. Drugs 44, 750-799. http://dx.doi.org/10.2165/00003495-199244050-00007.

[20] Riegelman S, Loo J & Rowland M 1968, Concept of a volume of distribution and possible errors in evaluation of this parameter. Journal of Pharmaceutical Sciences 57, 128-133. http://dx.doi.org/10.1002/jps.2600570125.

[21] Riggs DS 1964, the Mathematical Approach to Physiological Problems. Academic Medicine 39, 235.

[22] Rodvold KA 1999, Clinical pharmacokinetics of clarithromycin. Clinical Pharmacokinetics 37, 385-398. http://dx.doi.org/10.2165/00003088-199937050-00003.

[23] Rosenbaum SE 2012, Basic pharmacokinetics and pharmacodynamics: An integrated textbook and computer simulations: John Wiley & Sons.

[24] Thrall MA, Weiser G, Allison R & Campbell TW 2012, Veterinary hematology and clinical chemistry: John Wiley & Sons.

[25] Traunmuller F, Zeitlinger M, Zeleny P, Muller M & Joukhadar C 2007, Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrobial Agents and Chemotherapy 51, 3185-3189. http://dx.doi.org/10.1128/AAC.00532-07.

[26] Watkins J & Klaassen CD 1986, Xenobiotic biotransformation in livestock: comparison to other species commonly used in toxicity testing. Journal of Animal Science 63, 933-942.

[27] Wimsatt J, Johnson J, Mangone BA, Tothill A, Childs JM & Peloquin CA 1999, Clarithromycin pharmacokinetics in the desert tortoise (Gopherus agassizii). Journal of Zoo and Wildlife Medicine 36-43.

[28] Womble AY, Giguère S, Lee EA & Vickroy TW 2006, Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals. American Journal of Veterinary Research 67, 1681-1686. http://dx.doi.org/10.2460/ajvr.67.10.1681.

[29] Zhang X, Zou M, Li S, Chen X & Zhong D 2008, Bioavailability of clarithromycin cyclodextrin ternary complexes upon oral administration to healthy beagle dogs. Drug Development and Industrial Pharmacy 34, 1048-1053. http://dx.doi.org/10.1080/03639040801937474.

Downloads

Published

2016-03-11

Issue

Section

Articles